Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Gets Green Light For Risk-Benefit Analysis From Ephedra Ruling

This article was originally published in The Tan Sheet

Executive Summary

An appellate court decision upholding FDA's ban of ephedra "will embolden FDA to challenge products that have a bad safety profile," according to Scott Bass, a food and drug law expert and partner at Sidley Austin (Washington, DC)

Related Content

Supreme Court Refuses Ephedra Case, Battle Against Risk-Benefit Continues
Hatch, Cannon Oppose Risk-Benefit For Ephedra; Experts Discuss NPA Brief
NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA
Will Nutraceutical Succeed In Asking Supreme Court To Review Ephedra Ban?
Nutraceutical Files For Appellate Court Rehearing Of Ephedra Ban Suit
CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
FDA Appeals Utah Ephedra Court Ruling, Defends Use Of Risk/Benefit Analysis
Utah Court Overturns Ephedra Ban For Low-Dose Products
Utah Court Overturns Ephedra Ban For Low-Dose Products





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts